The main risk is sequencing, not product relevance. Stem likely has enough real technology and installed workflow depth to matter, but the company must preserve liquidity long enough for higher-margin software, controls, and verification revenue to become unmistakable. If project timing slips,
OEM bundles win, or financing terms worsen, much of the operating improvement can be absorbed before equity holders fully benefit.